Mizuho analyst Graig Suvannavejh raised the firm’s price target on Neumora Therapeutics (NMRA) to $5 from $4 and keeps an Outperform rating on the shares following last week’s introduction of NMRA-861. The firm projects a U.S. launch in 2034 and risk-unadjusted NMRA-861 sales of $1.2B in 2037. It sees a favorable risk/reward at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA: